Remodelin

• Description:

  Remodelin is an orally active and selective inhibitor of acetyltransferase NAT10. Remodelin inhibits NAT10 activitity and slows DNA replication and suppresses growth of prostate cancer cells. Remodelin inhibits the growth of prostate cancer and hepatocellular carcinoma in xenograft model. Remodelin enhances the healthspan in hutchinson-gilford progeria syndrome (HGPS) mouse model[1][2][3][4].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Histone Acetyltransferase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Remodelin.html

• Purity:

  99.84

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  N#CC1=CC=C(C2=CSC(N/N=C3CCCC/3)=N2)C=C1

• Molecular Formula:

  C15H14N4S

• Molecular Weight:

  282.36

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Larrieu D, et al. Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science. 2014 May 2;344 (6183) :527-32.|[2]Ma N, et.al. Inhibition of N-Acetyltransferase 10 Suppresses the Progression of Prostate Cancer through Regulation of DNA Replication. Int J Mol Sci. 2022 Jun 12;23 (12) :6573. |[3]Balmus G, et.al. Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Nat Commun. 2018 Apr 27;9 (1) :1700. |[4]Zhang X, et.al. N-Acetyltransferase 10 Enhances Doxorubicin Resistance in Human Hepatocellular Carcinoma Cell Lines by Promoting the Epithelial-to-Mesenchymal Transition. Oxid Med Cell Longev. 2019 Jul 1;2019:7561879.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Citation 01:

  Adv Sci (Weinh) . 2025 Dec;12 (46) :e04245.|bioRxiv. 2023 Feb 11.|Cell Death Dis. 2023 Nov 1;14 (11) :712.|Cell Rep. 2023 Jul 17;42 (7) :112810.|J Agric Food Chem. 2022 Jan 12;70 (1) :403-414.|J Hazard Mater. 2025 Oct 19:499:140193.|J Virol. 2024 Jan 23;98 (1) :e0135023.|Life Sci. 2023 Oct 1:330:121948.|Acta Pharmacol Sin. 2023 Oct;44 (10) :2125-2138.|bioRxiv. 2025 Sep 1:2025.09.01.673489.|Epigenetics. 2024 Dec;19 (1) :2417158.|Heliyon. 2023 Jun 8;9 (6) :e17103.|iScience. 2025 Jun 9;28 (7) :112860.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Oncogene. 2021 Apr;40 (15) :2711-2724.|SSRN. 2025 Jul 28.

• CAS Number:

  [949912-58-7]